| Total N (%) | SUVmax Mean ± SD | P | SUVpeak Mean ± SD | P | TLR Mean ± SD | P | MTV (cm3) Mean± SD | P |
---|---|---|---|---|---|---|---|---|---|
 | 297 (100) | 7.57 ± 4.41 |  | 5.49 ± 3.42 |  | 4.72 ± 5.50 |  | 3.42 ± 2.00 |  |
Age, years | Â | Â | 0.379 | Â | 0.380 | Â | 0.174 | Â | 0.784 |
 < 40 | 35 (11.8) | 8.08 ± 4.35 |  | 5.85 ± 3.29 |  | 3.79 ± 1.97 |  | 4.04 ± 3.38 |  |
 ≥ 40 | 262 (88.2) | 7.50 ± 4.42 |  | 5.44 ± 3.44 |  | 3.37 ± 2.01 |  | 4.81 ± 5.73 |  |
T stage | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 |
 T1 | 59 (19.9) | 5.87 ± 3.25 |  | 3.72 ± 2.18 |  | 2.63 ± 1.41 |  | 1.40 ± 1.54 |  |
 T2 | 238 (80.1) | 7.99 ± 4.56 |  | 5.93 ± 3.53 |  | 3.62 ± 2.08 |  | 5.55 ± 5.82 |  |
N stage | Â | Â | 0.112 | Â | 0.018 | Â | 0.089 | Â | < 0.001 |
 N0 | 150 (50.5) | 7.99 ± 4.69 |  | 5.95 ± 3.63 |  | 3.62 ± 2.13 |  | 5.59 ± 5.74 |  |
 N1 | 147 (49.5) | 7.14 ± 4.07 |  | 5.02 ± 3.14 |  | 3.22 ± 1.85 |  | 3.84 ± 5.12 |  |
TNM stage | Â | Â | 0.225 | Â | 0.081 | Â | 0.225 | Â | 0.034 |
 IIA | 209 (70.4) | 7.39 ± 4.43 |  | 5.32 ± 3.43 |  | 3.34 ± 2.00 |  | 4.41 ± 5.28 |  |
 IIB | 88 (29.6) | 7.99 ± 4.35 |  | 5.89 ± 3.38 |  | 3.62 ± 2.01 |  | 5.47 ± 5.97 |  |
Pathologic prognostic stage | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | 0.005 |
 I | 167 (38.4) | 6.29 ± 3.34 |  | 4.52 ± 2.46 |  | 2.87 ± 1.53 |  | 3.70 ± 4.72 |  |
 II | 113 (17.8) | 9.10 ± 4.98 |  | 6.55 ± 3.91 |  | 4.09 ± 2.29 |  | 5.69 ± 5.97 |  |
 III | 17 (32.3) | 9.98 ± 5.46 |  | 7.90 ± 4.77 |  | 4.47 ± 2.36 |  | 8.29 ± 6.98 |  |
Grade | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 |
 1 | 43 (14.5) | 5.16 ± 2.90 |  | 3.67 ± 2.16 |  | 2.36 ± 1.33 |  | 2.33 ± 3.09 |  |
 2 | 110 (37) | 6.21 ± 3.24 |  | 4.44 ± 2.43 |  | 2.79 ± 1.46 |  | 3.76 ± 4.94 |  |
 3 | 144 (48.5) | 9.33 ± 4.84 |  | 6.83 ± 3.83 |  | 4.22 ± 2.21 |  | 6.17 ± 6.06 |  |
ER | Â | Â | < 0.001 | Â | 0.001 | Â | < 0.001 | Â | < 0.001 |
 Positive | 194 (65.3) | 6.32 ± 3.36 |  | 4.55 ± 2.52 |  | 2.86 ± 1.51 |  | 3.98 ± 5.16 |  |
 Negative | 103 (34.7) | 9.92 ± 5.14 |  | 7.25 ± 4.14 |  | 4.48 ± 2.36 |  | 6.12 ± 5.88 |  |
PR | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 |
 Positive | 178 (59.9) | 6.39 ± 3.34 |  | 4.58 ± 2.47 |  | 2.91 ± 1.52 |  | 3.70 ± 4.65 |  |
 Negative | 119 (40.1) | 9.34 ± 5.17 |  | 6.85 ± 4.13 |  | 4.20 ± 2.36 |  | 6.25 ± 6.30 |  |
HER2 | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | 0.016 |
 Positive | 55 (18.5) | 9.12 ± 4.20 |  | 6.49 ± 2.96 |  | 4.29 ± 2.14 |  | 5.42 ± 5.12 |  |
 Negative | 242 (81.5) | 7.22 ± 4.39 |  | 5.26 ± 3.48 |  | 3.23 ± 1.92 |  | 4.56 ± 5.59 |  |
Luminal type | Â | Â | 0.139 | Â | 0.115 | Â | 0.162 | Â | 0.103 |
 Luminal A | 174 (58.6) | 7.44 ± 4.68 |  | 5.46 ± 3.59 |  | 3.38 ± 2.14 |  | 4.79 ± 5.75 |  |
 Luminal B | 25 (8.4) | 6.82 ± 3.79 |  | 4.63 ± 2.52 |  | 3.07 ± 1.63 |  | 2.69 ± 2.24 |  |
 HER2 positive | 30 (10.1) | 6.71 ± 2.73 |  | 4.62 ± 2.23 |  | 2.99 ± 1.11 |  | 3.50 ± 4.18 |  |
 Triple negative | 68 (22.9) | 8.56 ± 4.39 |  | 6.25 ± 3.57 |  | 3.85 ± 2.03 |  | 5.83 ± 5.96 |  |
Ki-67 | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | 0.031 |
 < 14% | 35 (11.8) | 5.19 ± 2.65 |  | 3.70 ± 1.98 |  | 2.30 ± 1.14 |  | 3.99 ± 6.54 |  |
 ≥ 14% | 262 (88.2) | 7.89 ± 4.50 |  | 5.73 ± 3.50 |  | 3.57 ± 2.05 |  | 4.82 ± 5.36 |  |
Hormonal therapy | Â | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 | Â | < 0.001 |
 Yes | 181 (60.9) | 6.34 ± 3.27 |  | 4.53 ± 2.46 |  | 2.86 ± 1.45 |  | 3.71 ± 4.55 |  |
 No | 116 (39.1) | 9.50 ± 5.21 |  | 6.99 ± 4.11 |  | 4.30 ± 2.40 |  | 6.30 ± 6.43 |  |
HER2-targeted therapy | Â | Â | 0.001 | Â | 0.003 | Â | < 0.001 | Â | 0.027 |
 Yes | 49 (16.5) | 9.17 ± 4.22 |  | 6.44 ± 2.95 |  | 4.28 ± 2.14 |  | 5.36 ± 5.12 |  |
 No | 248 (83.5) | 7.26 ± 4.38 |  | 5.30 ± 3.48 |  | 3.25 ± 1.93 |  | 4.60 ± 5.58 |  |
Adjuvant chemotherapy | Â | Â | 0.128 | Â | 0.051 | Â | 0.178 | Â | 0.012 |
 Yes | 274 (92.3) | 7.46 ± 4.37 |  | 5.37 ± 3.36 |  | 3.38 ± 1.99 |  | 4.46 ± 5.18 |  |
 No | 23 (7.7) | 8.91 ± 4.74 |  | 6.85 ± 3.84 |  | 3.92 ± 2.08 |  | 7.90 ± 7.98 |  |